Acurx Pharmaceuticals, Inc. financial data

Symbol
ACXP on Nasdaq
Location
259 Liberty Avenue, Staten Island, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Acurx Pharmaceuticals, LLC (to 6/23/2021)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 277 %
Debt-to-equity 75.3 % +65.3%
Return On Equity -392 % -75.6%
Return On Assets -103 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.9M shares +22.7%
Common Stock, Shares, Outstanding 16.8M shares +29%
Entity Public Float 27.9M USD -6.38%
Common Stock, Value, Issued 16.8K USD +29%
Weighted Average Number of Shares Outstanding, Basic 16.4M shares +25.8%
Weighted Average Number of Shares Outstanding, Diluted 16.4M shares +25.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.52M USD +17.9%
General and Administrative Expense 9.91M USD +37.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -16.4M USD -29.2%
Earnings Per Share, Basic -1.09 USD/shares -3.81%
Earnings Per Share, Diluted -1.09 USD/shares -3.81%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 5.98M USD -16.4%
Assets 6.58M USD
Employee-related Liabilities, Current 247K USD +19.5%
Liabilities, Current 3.32M USD +2.96%
Liabilities 3.32M USD +2.96%
Retained Earnings (Accumulated Deficit) -64.5M USD -34.2%
Stockholders' Equity Attributable to Parent 2.66M USD -32.3%
Liabilities and Equity 5.98M USD -16.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.06M USD -58.5%
Net Cash Provided by (Used in) Financing Activities 4.51M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 16.8M shares +29%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.45M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.76M USD -18.3%
Deferred Tax Assets, Valuation Allowance 11.9M USD +67.7%
Deferred Tax Assets, Gross 11.9M USD +67.7%
Deferred Tax Assets, Operating Loss Carryforwards 5.52M USD +64.2%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 67.2M USD +29.1%